Landfill mining from extractive waste facilities: The importance of a correct site characterisation and evaluation of the potentialities. A case study from Italy

Raw materials (RM) and critical raw materials (CRM; EC, 2017) supply is essential to both the maintenance and development of the EU economy as its industries rely on a steady RM supply. Thus, securing a sustainable RM and CRM supply and their circular use in the economy is of importance at EU level and beyond (Blengini et al., 2017, Coulomb et al., 2015, Vidal-Legaz et al., 2016). Furthermore, the developments of clean technologies coupled with economic growth exacerbate the short and long-term demand and needs (Blagoeva et al., 2016, Pavel and Tzimas, 2016). For example, Habib and Wenzel (2014) reported that the necessary supply Nd and Dy will grow from 10.0 Gg to 54.5 Gg and 0.5 Gg to 4.95 Gg respectively from 2010 to 2050

Industry 4.0 perspectives in the health sector in Brazil

Health 4.0 can be understood as the set of procedures that seek to improve the efficiency and speed of health professionals with possible guidelines for combining patient data in hospitals. However, systematizing and qualitatively describing the contributions of industry 4.0 in the context of the Brazilian health sector is a complex task. The aim of this paper is to present an analysis of industry 4.0 related to the health sector and its respective characteristics in Brazil. In addition, it discusses the prospects for greater use of technology in health care. In methodological terms, an exploratory field research was conducted with a non-random and intentional sample of professionals working in the technological context of Brazilian health. The research is classified as descriptive and qualitative, exploratory. The results contribute to narrow the information gap about industry 4.0 in the Brazilian health sector. The study allowed to develop a concept map of health 4.0 regarding the professional profile, considering the adoption of technologies that may favor the sector

Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience

Abstract In idiopathic thrombocytopenic purpura (ITP), corticosteroids have been widely recognized as the most appropriate first-line treatment, even if the best therapeutic approach is still a matter of debate. Recently, a single high-dose dexamethasone (HD-DXM) course was administered as first-line therapy in adult patients with ITP. In this paper we show the results of 2 prospective pilot studies (monocentric and multicentric, respectively) concerning the use of repeated pulses of HD-DXM in untreated ITP patients. In the monocenter study, 37 patients with severe ITP, age at least 20 years and no more than 65 years, were enrolled. HD-DXM was given in 4-day pulses every 28 days, for 6 cycles. Response rate was 89.2%; relapse-free survival (RFS) was 90% at 15 months; long-term responses, lasting for a median time of 26 months (range 6-77 months) were 25 of 37 (67.6%). In the multicenter study, 95 patients with severe ITP, age at least 2 years and no more than 70 years, were enrolled. HD-DXM was given in 4-day pulses every 14 days, for 4 cycles; 90 patients completed 4 cycles. Response rate (85.6%) was similar in patients classified by age (< 18 years, 36 of 42 = 85.7%; ≥ 18 years, 41 of 48 = 85.4%, P = not significant), with a statistically significant difference between the second and third cycle (75.8% vs 89%, P = .018). RFS at 15 months 81%; long-term responses, lasting for a median time of 8 months (range 4-24 months) were 67 of 90 (74.4%). In both studies, therapy was well tolerated. A schedule of 3 cycles of HD-DXM pulses will be compared with standard prednisone therapy (eg, 1 mg/kg per day) in the next randomized Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) trial

Phreatic sulphide bearing quartz breccias between crystalline basement and Collio formation (Southern Alps, Italy)

In this work a report is given of the geological, petrographic and ore mineralogical features of several sulphide-bearing quartz breccia (SQB) bodies outcropping in a structurally complex sector of the Orobic Alps (Southern Alpine domain) and close to the uranium-rich mining area of Novazza. Although little studied, these breccia bodies were previously attributed to different genetic processes and/or geological domains (e.g., Crystalline Basement, Basal Conglomerate formation). The features of the SQB bodies suggest a hydrothermal origin likely related to the large-scale hydrothermal process causing the formation of the nearby uranium ore deposit at Novazz

Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future

The use of fetal bovine serum (FBS) as a cell culture supplement is discouraged by regulatory authorities to limit the risk of zoonoses and xenogeneic immune reactions in the transplanted host. Additionally, FBS production came under scrutiny due to animal welfare concerns. Platelet derivatives have been proposed as FBS substitutes for the ex-vivo expansion of mesenchymal stem/stromal cells (MSCs) since platelet-derived growth factors can promote MSC ex-vivo expansion. Platelet-derived growth factors are present in platelet lysate (PL) obtained after repeated freezing-thawing cycles of the platelet-rich plasma or by applying physiological stimuli such as thrombin or CaCl2.PL-expanded MSCs have been used already in the clinic, taking advantage of their faster proliferation compared with FBS-expanded preparations. Should PL be applied to other biopharmaceutical products, its demand is likely to increase dramatically. The use of fresh platelet units for the production of PL raises concerns due to limited availability of platelet donors. Expired units might represent an alternative, but further data are needed to define safety, including pathogen reduction, and functionality of the obtained PL. In addition, relevant questions concerning the definition of PL release criteria, including concentration ranges of specific growth factors in PL batches for various clinical indications, also need to be addressed. We are still far from a common definition of PL and standardized PL manufacture due to our limited knowledge of the mechanisms that mediate PL-promoting cell growth. Here, we concisely discuss aspects of PL as MSC culture supplement as a preliminary step towards an agreed definition of the required characteristics of PL for the requirements of manufacturers and users